Within the late 2010s, scientists on the Danish drugmaker Novo Nordisk developed a brand new weekly weight problems remedy that focused three hormones without delay. In mice research, the drug, which activated receptors of the GLP-1, GIP, and glucagon hormones, precipitated notable weight reduction.
However Novo shelved the remedy. The corporate was involved about potential unwanted side effects of concentrating on glucagon, like rising blood sugar and coronary heart price. Moreover, Novo already had one other weight problems remedy in growth that confirmed nice promise — the GLP-1 drug semaglutide, now bought beneath the model identify Wegovy.
“I simply by no means felt there was a conviction inside Novo to combat by way of the obstacles” with glucagon, similar to attempting out slower titration schedules to handle unwanted side effects, mentioned Richard DiMarchi, a chemist who led the event of the triple agonist in an Indianapolis analysis heart.
As that molecule collected mud, not distant, Indianapolis-based drugmaker Eli Lilly was quickly shifting alongside its personal triple agonist, referred to as retatrutide. At the moment, that medicine is in late-stage testing and seen as one of many business’s most promising weight problems drug candidates.
For some former Novo workers, the little-known episode is a window into the corporate’s overly conservative strategy to weight problems medication — an strategy that will clarify why, despite the fact that Novo was the primary to promote a brand new technology of weight problems medication, it’s now broadly seen as trailing Lilly in a market that some predict might balloon to over $100 billion by the tip of the last decade.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
